Paradigm Biocapital Advisors’s Cogent Biosciences COGT Stock Holding History

Paradigm Biocapital Advisors’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,156,398	Closed	-$45.3M	–	35
2025 Q3	$45.3M	Sell	3,156,398 -7,196,051	-70%	-$85.3M	1.29%	23
2025 Q2	$74.3M	Buy	10,352,449 +1,388,794	+15%	+$7.7M	3.17%	9
2025 Q1	$53.7M	Buy	8,963,655 +4,046,243	+82%	+$31.7M	2.46%	12
2024 Q4	$38.4M	Buy	4,917,412 +307,650	+7%	+$3.07M	1.33%	19
2024 Q3	$49.8M	Buy	4,609,762 +985,420	+27%	+$9.59M	1.68%	18
2024 Q2	$30.6M	Buy	+3,624,342	New	+$27.5M	1.17%	24
2023 Q4	–	Sell	-225,605	Closed	-$2.2M	–	31
2023 Q3	$2.2M	Buy	+225,605	New	+$2.68M	0.15%	31

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paradigm Biocapital Advisors's COGT Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 3,156,398 shares — an estimated $45.3M sold.

Paradigm Biocapital Advisors first reported a position in COGT in Q3 2023 and held it in 7 quarters. The position peaked at $74.3M in Q2 2025. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

Paradigm Biocapital Advisors reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
Paradigm Biocapital Advisors sold 3,156,398 Cogent Biosciences shares in Q4 2025, an estimated $45.3M.
Paradigm Biocapital Advisors first reported a position in Cogent Biosciences in Q3 2023 and held it in 7 quarters.
Paradigm Biocapital Advisors's Cogent Biosciences position peaked at $74.3M in Q2 2025.
267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.